Notice of extraordinary general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 24 ...
Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer
Interview features OPTIMIZE-1 Principal Investigator Jean-Luc Van Laethem from Erasmus Hospital and Alligator CMO Sumeet Ambarkhane OPTIMIZE ...
Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Alligator Bioscience AB (publ) today announces that Tova Landström, PhD, Medical Science Director at Alligator, has been appointed as employ ...
Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Laura von Schantz, employee representative, has resigned from the Alligator Bioscience AB Board of Directors, effective February 14, 2023, f ...
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 Lund, Sweden, and Seattle, Washington, February ...
Alligator Bioscience Announces the Promotion of Laura von Schantz to Chief Technology Officer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the promotion of Laura von Schantz to Chief Technology O ...
Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...
Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate
52% Objective Response Rate in pre-planned interim efficacy analysis of mitazalimab combined with mFOLFIRINOX in 1st line metastatic pancrea ...
Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement
The second project aims to develop a bispecific antibody with potential applications in solid tumors Alligator and Orion each to provide val ...